NeuroSense Therapeutics Ltd【NRSN】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial PR...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy...

Form EFFECT - Notice of Effectiveness

runncoach 5時間前

If the company has to do another bridge money raise until a partnership, the recent filings of the last money raise likely show the reason the price remains so low IMO. The "most favored nations" clause tends to cap the share prices. That's besides the millions of warrant shares. Hopefully a buck and change holds.

👍️0

runncoach 5時間前

Folks should be careful. If they don't get things finalized we could be looking at a reverse split. Partnerships don't always work out. Regardless, no sales in 2025 but hopefully they launch the P3 this summer as they project.

👍️0

johnhancoque 7時間前

Just gained nasdaq compliance and now threatening it. If anything, this is an emberassing complication for the ceo. Something needs to change here because the hedge funds are clearly in violation of manipulating the share price. The market cap is only 19 million. The ceo needs to up his game and get some positive pr happening or these guys will continue to manipulate the share price every day

👍️0

johnhancoque 3週前

Um...when was it approved? Blockbuster status won't be known until it's selling around the world, which won't be hard now with Big Pharma backing them. Your understanding of bios is very limited. Widen your horizons and stop wasting your time here as what you post makes very little sense anyways

👍️0

runncoach 3週前

Must have not been blockbuster, eh?

👍️0

johnhancoque 3週前

https://finance.yahoo.com/news/neurosense-therapeutics-enters-binding-term-140000065.html

👍️0

johnhancoque 3週前

Nobody claims a multibillion dollar partnership. Read the headlines. They are in discussions with several multi- billion dollar companies for partnerships. Also, they could have done a large public offering to keep the lights on as they are nasdaq listed. Instead the ceo chose to do a private placement and buy 5 million worth. The partnerships are for funding the continued trials and I know alot about how things work with pharma as I've been trading bios 20 years. The data is impressive and worth Billions and as the market catches on expect significant rises in the share price

👍️0

runncoach 3週前

How much do you think a P3 cost? That's why so little leverage. Why didn't they already get a partnership they've talked about for 4 months? It's not easy when you don't have cash. It's not going to be a multi billion partnership that I've seen some posting about. Ceo kept them listed and gave a couple months breathing room. Congrats to him

👍️0

johnhancoque 3週前

Right. You believe he did it to keep the lights on when he could have done a public offering for alot more. Instead, he spent 5 million of his own money suggesting he has faith in a very large partnership. Your way of thinking is twisted. No need reply again

👍️0

runncoach 3週前

I'm suggesting he bought to keep the company's listing and float the company til they find funding since they can't fund a P3 trial. It's not a strong position to negotiate from. I don't think I'm saying anything controversial or that isn't common sense at this point. I expect them to find something and then there will be a very long wait

👍️0

johnhancoque 3週前

You're suggesting the ceo bought 5 million worth of stock this month well above market value because he may not succeed in finding a partner? That sounds ridiculous buddy. It's more likely he is very confident in finding a partnership or is in the final stages so he bought 5 million worth. Your understanding of how insiders buys shares is out to bloody lunch. Hardly anyone would spend 5 million on a single stock without a near sure bet let alone a ceo of a publicly traded company

👍️0

johnhancoque 3週前

A ceo who had no faith in a partnership sure as he'll wouldn't pony up 5 million bucks if there was nothing in the works. Don't miss the forest for the trees. He bought 5 million worth because a partnership is in the works.
Smh

👍️0

runncoach 3週前

Been here long before you. Ceo ponied up money to meet Nasdaq requirements. Stock got shorted down so the "raise" price would look better.

Doesn't take a genius to realize not having the cash to even make it to the start of launching a P3 next summer isn't negotiating from a position of strength. If they don't get a partnership there would have to be a very unfavorable money raise to launch the trial. Between a rock and a hard place as far as negotiating.

Let's hope they get a partnership on favorable terms and a nice spike before the stock pulls back with the markets realizing another 12+ months til Canadian news and much longer than that for US.

👍️0

johnhancoque 3週前

So now and ceo who buys 5 million worth of stock isn't a good sign, it's a bad sign of a pump? Where do you guys come from, really?
Even with good news you shorts twist things unrecognizable. Truly unbelievable
The ceo bought 5 million worth 30% above the then market price. They don't need cash they need a partnership which they will have no problem finding and are in discussions right now with several Big Pharmas. Drugs like this don't go unnoticed long with Big pharma sniffing around. Just sell and get lost because your comments are useless to the investing community

👍️0

runncoach 3週前

Was wondering about the pump.

Folks will soon learn you don't get billion dollar partnerships when the CEO is having to buy stock to keep the lights on I'm afraid. Give me 3 bucks and I'll sit this one out for a while.

👍️0

johnhancoque 3週前

$7.50 Cantor price target 🥱👀

👍️0

runncoach 3週前

Not immediately it won't, no. Not in a price sustainable way that is. I own shares but will sell any significant spikes and buy back lower to hold long term

👍️0

johnhancoque 3週前

You don't understand. A partnership with BP takes NRSN to the next level no looking back. Once a partnership is announced with a large upfront payment, there will be no looking back for this company, ever. It will be bought by BIg Pharma long before p3 results. Easy to manufacture and worldwide protection until 2044

👍️0

runncoach 3週前

The problem is there is a large number of warrant shares available that will keep a lid on the share price after any spikes. Company has low funds considering it has yet to begin their P3. Sales are 2-3 years away at the least. Details of any partnership will be very important concerning future potential money raises. Sell significant spikes is my advice because folks sitting on warrants likely will. JMHO

👍️0

johnhancoque 3週前

$9.25 price target. Partnership news looks imminent. Only 25 million market cap has 400% to run at a minimum here

👍️0

johnhancoque 3週前

CEO bought 5 million worth and no matter how you spin that it will always be a boon for the company and shareholders. Regardless of what you say, any ceo who puts up 5 million bucks and above market for that matter says everything about where the sp is headed nearterm and speaks volumes about the confidence he has in his company and the data. Simple as that!

👍️0

McMagyar 3週前

Except
The value would have already rocketed well past $1.25.. with so few shares out.. and after the news hit, the company could have raised the same amount of money by issuing fewer shares, less dilution, shares more valuable.. now only one shareholder benefits from knowing the good news.. sure looks like a shareholder lawsuit to me.. greed sucks.. maybe the other shareholders will let it go.. maybe they won't..
You can't control what happens, but you can control with whom you do bizness..
Thx Barrister.. wise words

👍️0

johnhancoque 3週前

All that matters is he bought 5 million shares @ $1.25 and the share price is about to rocket hard. Analysts price targets north of $12.00

👍️0

McMagyar 3週前

This smells a lot like stealing to me..
All the other shareholders got diluted.. while the sole stock buyer of issuance becomes kazillionairre.. sounds like an attorney would want to know what the shareholder who bought all this stock knew.. and why the offering wasn't made to other shareholders?

👍️0

johnhancoque 3週前

Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares

That would look quite a bit like inside trading if they did that the next couple months. Trust me I hope so but doesn't look good to me.

👍️0

johnhancoque 4週前

$25.00 with partnership and large upfront payment

👍️0

johnhancoque 4週前

Um....he sold himself the last offering because there is a multi Billion dollar partnership about to be signed

👍 1

McMagyar 1月前

It was a money raise to one guy.. total bullshit. Thief

👍️0

runncoach 1月前

The issue to me is the stock was sold down the last 2 or 3 weeks on "no news" and then we get a low price money raise. Doesn't look good

👍️0

McMagyar 1月前

Co issues 12,000,000 share rights to one guy right before good news hits? What a legal Scally wag.. what's to stop him from issuing himself another 10,000,000? Know them but their greed.
What a crock

👍️0

runncoach 1月前

Today's PR would certainly lead one to believe no partnership type of completion until next year at the earliest IMO

👍️0

runncoach 1月前

Just under 21 million

From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).

These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.

👍️0

runncoach 5月前

Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO

👍️0

vein 6月前

Thanks much for the insight !

👍️0

runncoach 6月前

Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level

👍️0

vein 6月前

Why the sell off ?? Thanks in advance!

👍️0

vein 6月前

Seems like a decent entry ?

👍️0

runncoach 6月前

The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.

👍️0

vein 6月前

Time to buy now ??? Newbie here! Any thoughts ??

Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.

Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr

👍️0

runncoach 9月前

Financing broke the stock for now. Either Biogen news or dead money IMO

👍️0

runncoach 9月前

Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.

👍️0

runncoach 9月前

And there's the money raise at 1.50

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

NeuroSense Therapeutics Ltd (NRSN)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

NRSN ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Form EFFECT - Notice of Effectiveness

NRSN Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

NeuroSense Therapeutics Ltd (NRSN) ニュース

NeuroSense Therapeutics Ltd (NRSN)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

NRSN ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Form EFFECT - Notice of Effectiveness

NRSN Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手